Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer

Author：                    

Publisher： Spandidos Publications

ISSN： 1792-1074

Source： Oncology Letters, Vol.2, Iss.3, 2011-01, pp. : 493-498

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study)

By Hebbar Mohamed   Tournigand Christophe   Lledo Gérard   Mabro May   André Thierry   Louvet Christophe   Aparicio Thomas   Flesch Michel   Varette Charles   de Gramont Aimery   Group (GERCOR) Oncology  

Cancer Investigation, Vol. 24, Iss. 2, 2006-05 ,pp. : 154-159

Informa Healthcare

Access to resources Recommend Favorite

XELIRI compared with FOLFIRI as a secondline treatment in patients with metastatic colorectal cancer

By                  

Oncology Letters, Vol. 8, Iss. 4, 2014-01 ,pp. : 1864-1872

Spandidos Publications

Access to resources Recommend Favorite

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)

By Maindrault-Goebel F.   Louvet C.   Andre T.   Carola E.   Lotz J.P.   Molitor J.L.   Garcia M.L.   Gilles-Amar V.   Izrael V.   Krulik M.   de Gramont A.  

European Journal of Cancer, Vol. 35, Iss. 9, 1999-09 ,pp. : 1338-1342

Elsevier

Access to resources Recommend Favorite

Development of Taste Disorders Following FOLFOX-FOLFIRI Therapy and Its Effects on The QOL of Patients with Colorectal Cancer

By Takimoto Norio   Sugawara Shiho   Iida Akiko   Sakakibara Takashi   Mori Kenji   Sugiura Mitsuru   Yamamura Keiko   Adachi Mamoru  

Japanese Journal of Cancer and Chemotherapy, Vol. 36, Iss. 3, 2009-03 ,pp. : 431-435

Sunmedia

Access to resources Recommend Favorite

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)

By Maindrault-Goebel F.   de Gramont A.   Louvet C.   Andre T.   Carola E.   Mabro M.   Artru P.   Gilles V.   Lotz J.P.   Izrael V.   Krulik M.   for the Oncology Multidisciplinary Research Group GERCOR  

European Journal of Cancer, Vol. 37, Iss. 8, 2001-05 ,pp. : 1000-1005

Elsevier

Access to resources Recommend Favorite